Skip to Main Content
Mobile Menu

Cheryl L. Jorcyk, Ph.D.

Full Professor, Department of Biological SciencesJOrcyk 2
Year arrived at BSU: 1997

Mailing Address:
Department of Biological Sciences
Boise State University
Boise, ID 83725-1515

Office Location: Science Building, Room 227
Office Number: 208-426-4287
Office Fax: 208-426-1040
E-Mail Address: cjorcyk@boisestate.edu

ACADEMIC DEGREES

B.S. in Biology, Pennsylvania State University, State College, PA, 1983
Ph.D. in Biology, The Johns Hopkins University, Baltimore, MD, 1991
Postdoctoral Fellowship, Intramural Research Training Award, National Cancer Institute, National Institutes of Health, 1992-1997

COURSES

BIOL 301 Cell Biology
BIOL 343 Genetics
BIOL 344/344G Molecular Cell & Genetics Laboratory
BIOL 441/541 Molecular Biology of Cancer
BIOL 441SL/541SL Molecular Biology of Cancer Service-Learning
BIOL 465/565 Advanced Topics in Molecular Biological Techniques
BIOL 466/566 Molecular Studies of Cancer
BIOL 595 Readings and Discussion: Cancer Biology
BMOL 606 Grant/Proposal Writing
BMOL 616 Responsible Research Conduct

JOB OPENINGS

Postdoctoral Position: Postdoctoral opening is available in the Department of Biological Sciences, in conjunction with the Center of Biomedical Research Excellence (COBRE) in Matrix Biology, at Boise State University to study the molecular mechanisms of inflammatory cytokines in tumor cell-mediated extracellular matrix disruption resulting in breast cancer invasion and metastasis. This is a unique opportunity to join a team, which in addition to performing in vitro and in vivo investigations, is actively involved in clinical and translational studies and promotes cross-disciplinary collaboration in cell biology, molecular biology, biochemistry, biophysics, and biomaterials. Applicants should be independent, highly motivated individuals with a strong molecular, cellular, and biochemistry background and excellent research qualifications. Experience with animal models of cancer, confocal imaging, and in silico screening are preferred. Successful candidates must hold a doctoral degree, have a good publication record, and demonstrate excellent writing skills. Interested applicants should submit a CV, a brief statement of research skills/experience, and future goals. In addition, please provide contact information (including email addresses and phone numbers) for three references to: Dr. Cheryl L. Jorcyk, cjorcyk@boisestate.edu.

 

COMING EVENTS

TBA

RECENT ACTIVITIES

AACR Conference, Philadelphia, April 17-22, 2015

Idaho Academy of Sciences and Engineering (IASE) Symposium, Boise State University, March 19-20, 2015

November 12, 2014 at 3:00 p.m.
Multipurpose Building, room 118
Joel Garbow, Ph.D., Washington University School of Medicine, St. Louis, MO
MRI at the Interface of Basic and Clinical Cancer Science
Open to the public

October 30, 2014 at 12:00 p.m.
Dr. Cheryl Jorcyk: Validating oncostatin M as a therapeutic target for metastatic breast cancer
Idaho State University – BPSCI Department and the College of Pharmacy
Meridian, Room 735; Pocatello, Leonard Hall, Pharmacy 123

Halftime, Football vs. BYU, Wankun Sirichotiyakul PhotoOctober 24, 2014
“Buck Cancer” at the Boise State vs. BYU football game on ESPN. Money from pink T-shirt sales for the student-section “pink out” went to undergraduate breast cancer research at Boise State.
This half-time photograph includes lab members Hunter Covert, Ken Tawara, Matt Dillon, Katie Neal, Cheryl Jorcyk, and VP of Research at Boise State, Mark Rudin.

October 21, 2014 at 6:00 p.m.
Dr. Jorcyk joined a panel of cancer experts to answer questions and inform the public about breast cancer.
It was a free event, open to the public
14_UHS_BreastCancerForum_WebSlider

October 15, 2014 at 3:00 p.m.
Multipurpose Building, room 118
Hunter Covert, PhD student, Biomolecular Sciences
Research seminar on Cytokine-induced CD44: effects on human breast cancer invasion and metastasis
Open to the public

LAB RESEARCH INTERESTS

My laboratory’s research interests are directed towards elucidation of the molecular mechanisms that promote tumor progression. We have been working on the effects of the cytokine Oncostatin M (OSM) on breast tumor progression and metastasis. Oncostatin M (OSM), an IL-6 family cytokine, is produced by breast cancer cells and tumor-associated cells of the immune system, including macrophages and neutrophils. OSM has been shown to inhibit the proliferation of breast cancer cells, and this effect initially focused much attention on OSM as a potential breast cancer therapy. Data from our lab, however, suggests that OSM could actually contribute to tumor progression and the development of a metastatic state. We have shown that OSM induces vascular endothelial cell growth factor (VEGF), cyclooxygenase-2 (COX-2), cell detachment, and invasive capacity in vitro. In vivo studies have confirmed an important role for OSM in breast cancer metastasis to bone. Studies investigating OSM in prostate cancer are underway.

LAB MEMBERS

 

 

 

 

 

Danielle Hedeen, BS
Lab Manager

Ken Tawara, MS
PhD Student

Hunter Covert
PhD Student

Matt Dillon
Undergraduate, McNair student,  INBRE Summer Research Fellowship

Katie Neal
Undergraduate

Jessica Burlile, MSTI Pre-Medical Summer Fellowship
Undergraduate

Hannah Scott
Undergraduate

John Doherty
Capital High School, Murdock Charitable Trust Partner in Science

Steve Peckovich, PhD
NNU Research Faculty

RECENT PUBLICATIONS

Goyden J, Tawara K, Hedeen D, Wiley J, Oxford JT, and Jorcyk CL. The effect of OSM on MC3T3-E1 osteoblastic cells in simulated microgravity with radiation. PLoS ONE. In press.

Cannon B, Hiremath M, Jorcyk C, and Joshi A. CoVE: Colony visualization system for animal pedigrees. Visual Information Communication an Interaction (VINCI). In press.

Ryan RE, Martin B, Mellor L, Jacob RB, Tawara K, McDougal OM, Oxford JT, Jorcyk CL. Oncostatin M binds to extracellular matrix in a bioactive conformation: implications for inflammation and metastasis. Cytokine 72(1), 71-85, 2015. PMID: 25622278

Mikelonis D, Jorcyk, CL, Tawara, K, Oxford JT. Stuve-Wiedemann syndrome: LIFR and associated cytokines in clinical course and etiology. Orphanet J Rare Dis. 9, 1-11, 2014. PMID: 24618404

Nadelson, L, Jorcyk, C, Yang, D, Smith, J, Matson, S, Cornell, K, and Husting, V. “I Just Don’t Trust Them: The Development and Validation of an Assessment Instrument to Measure Trust in Science and Scientists”. School Science and Mathematics, 114(2), 76-86, 2014.

Bolin, C, Tawara, K, Sutherland, C, Redshaw, J, Aranda, P, Moselhy, J Anderson, R, and Jorcyk C.L. Oncostatin M promotes mammary tumor metastasis to bone and osteolytic bone degradation. Genes Cancer 3, 117-30, 2012. PMID: 23050044

Bolin, C., Sutherland, C., Tawara, K., and Jorcyk, C.L. Novel mouse mammary cell lines for in vivo bioluminescence imaging (BLI) of bone metastasis. Biol Proced 14, 6-12, 2012. PMID: 22510147.

Jorcyk, C.L., Kolev, M., Tawara, K., and Zubik-Kowal, B. Experimental versus numerical data for breast cancer progression. Journal of Nonlinear Analysis: Real World Applications 13, 78-84, 2012.

Aranda P.S., LaJoie D.M., Jorcyk C.L. Bleach gel: a simple agarose gel for analyzing RNA quality. Electrophoresis 33, 366-9, 2012. PMID: 22222980

Tawara, K. and Jorcyk, C.L. Clinical significance of interleukin-6 (IL-6) in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Management and Research 3, 177-89, 2011. PMID: 21625400

Zubik-Kowal, B., Jorcyk, C.L., and Kolev, M. Numerical experiments for mammary adenocarcinoma cell progression. Integral Methods in Science and Engineering, Springer, 2011, book chapter.

Graugnard, E., Cox, A., Lee, J., Jorcyk, C.L., Yurke, B., and Hughes, W.L. Operation of a DNA-based autocatalytic network in serum. Lecture Notes in Computer Science, 6518, 83, 2011.

Graugnard, E., Cox, A., Lee, J., Jorcyk, C.L., Yurke, B., and Hughes, W.L. Kinetics of DNA and RNA hybridization in serum and serum-SDS. IEEE Transactions on Nanotechnology 9, 603, 2010. PMID: 20967137

Jackiewicz, Z., Jorcyk, C.L., Kolev, M., and Zubik-Kowal, B. Correlation between animal and mathematical models for prostate cancer progression. Computation and Mathematical Methods in Medicine iFirst article, 1-12, 2009.

Halsted, KC, Bowen, KB, Bond, L, Jorcyk, CL, Fyffe, WE, Kronz, JD, Oxford, JT. Collagen alpha1(XI) in normal and malignant breast tissue. Modern Pathology 21:1246-54, 2008.

Jorcyk, C.L., Holzer, R.G., and Ryan, R.E.: Oncostatin M induces detachment and enhanced metastatic capacity in T-47D human breast carcinoma cells. Cytokine 33:323-336, 2006.

Queen, M.M., Ryan, R.E., Holzer, R.G., Keller-Peck, C.R., and Jorcyk, C.L.: Breast cancer cells stimulate neutrophils to produce Oncostatin M: potential implications for tumor progression. Cancer Research 65: 8896-8904, 2005.

MacDougall, C.A., Ide, A., Soares, C., Vargas, M., Holzer, R.G., and Jorcyk, C.L.: Involvement of the hepatocyte growth factor-met receptor signaling loop with the classical “3M” pathways in tumor progression of mouse prostate adenocarcinoma cells. The Prostate 64: 139-149, 2005.

Holzer, R.G., Tommack, M., Schlekeway, E., Ryan, R.E, and Jorcyk, C.L: Oncostatin M induces the detachment of a reservoir of invasive mammary carcinoma cells: the role of cyclooxygenase-2. Clinical and Experimental Metastasis 21:167-176, 2004.

Holzer, R.G., MacDougall, C., Atwood, C., Green, J.E., and Jorcyk, C.L. 2003. Development and characterization of a progressive series of hormone-responsive mammary adenocarcinoma cell lines derived from the C3(1)/SV40 Large T-antigen transgenic mouse model. Breast Cancer Research and Treatment 77:65-76.

Soares, C., Shibata, M.-A., Green, J.E. and Jorcyk, C.L.: 2002. Development of PIN and prostate adenocarcinoma cell lines: a model system for multistage tumor progression. Neoplasia 4: 112-120.

Calvo, A., Xiao, N., Simon, R., Kang, J., Best, C., Emmert-Buck, M., Jorcyk, C.L., and Green, J.E. 2002. Identification of genes in prostate tumor progression by cDNA microarray analysis in an in vitro model derived from C3(1)/T-antigen transgenic mice: down-regulation of selenoprotein-P in mouse and human prostate cancer. Cancer Research 62: 5325-35.

Wigginton, J.M., Park, J.W., Gruys, M.E., Young, H.A., Jorcyk, C.L., Back, T.C., Brunda, M.J., Strieter, R.M., Ward, J., Green, J.E. and Wiltrout, R.H. 2001. Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, fas/fas ligand gene expression, and mammary epithelial apoptosis. J. Immunol. 166: 1156-1168.

Green, J.E., Shibata, M.A., Yoshidome, K., Kiu, M.L., Jorcyk, C., Anver, M.R., Wigginton, J., Wiltrout, R., Shibata, E., Kaczmarczyk, S., Wang, W., Liu, Z.Y., Calvo, A. and Couldrey, C. 200. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 19: 1020-1027.

Shibata, M.-A., Yoshidome, K., Shibata, E., Jorcyk, C.L. and Green, J.E. 2000. Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21. Cancer Gene Therapy 1: 1-10.